(Aurastop©) in the Prevention of High Frequency Migraine with Aura
To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop®) in the prophylactic treatment of high frequency migraine with aura (MWA). According to the international headache classification (IHCD 3 ̊ beta version) the aura phenomena have a duration of 5 - 60 minutes for any of the usual disturbances (visual, somatosensory and speech disturbance) but no classification describes the frequency of this phenomena.
Open Access Library Journal - October 30, 2018
Aurastop© in Episodic Migraine
Prevention: A Multicentric Observational Study
To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5 hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop.) in the prophylactic treatment of episodic migraine without aura (MO). Methods: Eighty patients suffering from MO for at least 6 months with a monthly frequency of 3 to 8 attacks and 4 to12 headache days, were enrolled in this open study and treated with Aurastop twice daily per os for 3 months. The reduction of headache days per month was assessed as the primary end-point, while the secondary end-points were: 1) reduction of the number of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drug intake; 4) subjective change of pain intensity. Results: All the parameters significantly improved at the end of the observational period of treatment with Aurastop.
Open Access Library Journal - August 6, 2018
AURASTOP® in the Treatment of Migraine Aura
The phenomenon of aura is traditionally considered as a non-avoidable event occurring in about one quarter of migraine sufferers before the headache phase . Although previous trials on migraine treatment have clearly demonstrated the benefit conferred by some agents, including triptans, on migraine headache, as well as their time-dependent effect, the therapeutic potential of modulating the phenomenon of migraine aura before pain occurrence has not been investigated so far …
OMMEGA Publishers - August 15, 2018
LA FISIOPATOLOGIA DELL'AURA EMICRANICA:
DALLA RICERCA ALLA CLINICA
L’emicrania è un disturbo neurologico ricorrente, caratterizzato da uno sviluppo della crisi in più fasi distinte. In circa il 7% dei casi, prima dell’inizio della fase del dolore, il paziente può fare esperienza dell’aura emicranica, che è definita come sintomi neurologici che durano generalmente non più di 60 minuti e potrebbero essere seguiti o accompagnati da dolore cefalico. I sintomi focali più comuni che caratterizzano l’aura emicranica sono visivi, sotto forma di scotomi scintillanti...
INSERTO GIORNALE DELLE CEFALEE - GIUGNO 2017
A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop®) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study
Open Access Library Inc. - June 8, 2017
Combination of Tanacethum Partenium, 5-Hydrossitriptophan (5-Http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP®) An Observational Study
OMMEGA Publishers - August 11, 2017